We are excited to announce that our Chief Operating Officer, Dr. Krystle Karoscik, has been invited to speak and present INNOVOTEX at the Women Founders Showcase on March 5th at Pennovation Works in Philadelphia. This event will feature six women-led companies making waves in their industries, with an expanded panel of investors and entrepreneurs who will discuss the challenges and opportunities facing women founders.
Admission and parking are free, but registration is required for security. You can reserve your spot here: https://bit.ly/AccelerateAction
About COO Krystle Karoscik
Dr. Karoscik has >15 years of professional experience in translational medicine and the pharmaceutical industry. She is an alumna of the University of Pennsylvania, trained in cell and gene therapy and clinical research. She has since led over 20 oncology programs through early-stage clinical trials. Dr. Karoscik has expertise in developing business optimization models to advance translational research through commercialization, for which she has received multiple Innovation Excellence awards from the Center for Advancing Innovation. With a strong connection to the Penn community, she serves as Vice President of the Board of Directors for the Penn Club of Boston (2024 recipient of the Alumni Club of Merit) and is Co-Chair of the Women in Leadership initiative to foster professional growth and development in STEM and finance. She volunteers as a Penn Alumni Ambassador and supports life science investments through Wharton Alumni Angels.
About INNOVOTEX
INNOVOTEX is an oncology therapeutic company that is developing a platform of macrocycle based assets to treat solid tumors. Its lead clinical candidate, NOVO-111 localizes to solid tumors and targets the cancer ribosome. Pre-clinical studies have demonstrated the ability of single agent, NOVO-111 to circumvent platinum-based resistance in wt-p53 in vivo models with statistically significant tumor regression. NOVO-111 has the potential to address unmet needs in multiple indications that present significant resistance to standard of care treatments, including NSCLC, CRC, ovarian, and pancreatic cancers.
Please reach out to find out more about INNOVOTEX and its current objectives.